갑상선 미세침흡인세포검사 슬라이드에서 BRAF Mutation 검출을 통한 갑상선 유두암의 진단
Diagnosis of Papillary Thyroid Cancer via Detection of BRAF Mutation on Fine Needle Aspiration Cytology Slides
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The prevalence rate of the BRAF mutation in papillary thyroid cancer (PTC) is as high as about 52 to 83% in Korea. Preoperative detection of BRAF mutation on fine needle aspiration cytology (FNAC) slides may help the surgeon make better therapeutic decisions. The present study aims to assess the feasibility of the mutant allele specific amplification (MASA) and restriction fragment length polymorphism (RFLP) method with using conventional FNAC slides and we also wanted to evaluate the clinical role of preoperatively detecting BRAF mutation. Methods: We extracted the genomic DNA from 59 FNAC slides and performed direct sequencing (DS) for detecting BRAF mutation. We could use only 17 slides for the MASA method and 6 slides for the RFLP method due to the shortage of extracted DNA. Additionally, we retrospectively analyzed the cases for which a histological diagnosis could be made. Results: Genomic DNA was extracted from 23 out of the 59 FNAC slides. The BRAF mutation status could be assessed via DS in 33 out of the 59 FNAC slides. The concordance between the MASA method and DS and the RFLP method and DS was 36.3% and 66.7% respectively. The positive and negative predictive value of the 13 indeterminate nodules was 87.5% and 20%, respectively. We could not find any association between the BRAF mutations and the alleged risk factors of PTC. Conclusion: We believe that the purity and the amount of the DNA template must be increased to detect BRAF mutation with using a FNAC slide. Preoperative detection of the BRAF mutation on a FNAC slide may refine the cytological diagnosis, but the application of assessing BRAF mutation as a prognostic marker is debatable. (Korean J Endocrine Surg 2010;10:12-18)
Abstract
Purpose: The prevalence rate of the BRAF mutation in papillary thyroid cancer (PTC) is as high as about 52 to 83% in Korea. Preoperative detection of BRAF mutation on fine needle aspiration cytology (FNAC) slides may help the surgeon make better therapeutic decisions. The present study aims to assess the feasibility of the mutant allele specific amplification (MASA) and restriction fragment length polymorphism (RFLP) method with using conventional FNAC slides and we also wanted to evaluate the clinical role of preoperatively detecting BRAF mutation. Methods: We extracted the genomic DNA from 59 FNAC slides and performed direct sequencing (DS) for detecting BRAF mutation. We could use only 17 slides for the MASA method and 6 slides for the RFLP method due to the shortage of extracted DNA. Additionally, we retrospectively analyzed the cases for which a histological diagnosis could be made. Results: Genomic DNA was extracted from 23 out of the 59 FNAC slides. The BRAF mutation status could be assessed via DS in 33 out of the 59 FNAC slides. The concordance between the MASA method and DS and the RFLP method and DS was 36.3% and 66.7% respectively. The positive and negative predictive value of the 13 indeterminate nodules was 87.5% and 20%, respectively. We could not find any association between the BRAF mutations and the alleged risk factors of PTC. Conclusion: We believe that the purity and the amount of the DNA template must be increased to detect BRAF mutation with using a FNAC slide. Preoperative detection of the BRAF mutation on a FNAC slide may refine the cytological diagnosis, but the application of assessing BRAF mutation as a prognostic marker is debatable. (Korean J Endocrine Surg 2010;10:12-18)
참고문헌 (25)
- Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
- Xing M, "BRAF mutation in thyroid cancer", Endocr Relat Cancer, 12, pp.245~262 (2005)
- Garnett MJ, "Guilty as charged: B-RAF is a human oncogene Cancer", Cell, 6, pp.313~319 (2004)
- Cohen Y, "BRAF mutation in papillary thyroid carcinoma", J Natl Cancer Inst, 95, pp.625~627 (2003)
- Soares P, "BRAF mutations and RET", PTC rearrangements are alternative events in the etiopathogenesis of PTC, 2003, pp.22, 4578~4580
- Xing M, "BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications", Endocr Rev, 28, pp.742~762 (2007)
- Hai-Rim Shin, "2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals", Cancer Research and Treatment, 36(2), pp.103~114 (2004), 대한암학회
- Kim TY, "The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma", Clin Endocrinol (Oxf), 63, pp.588~593 (2005)
- 김경희, "Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population", Yonsei Medical Journal, 45(5), pp.818~821 (2004), 연세대학교의과대학
- Chow LS, "Nondiagnostic thyroid fine-needle aspiration cytology: management dilemmas", Thyroid, 11, pp.1147~1151 (2001)
- Usami S, "Rapic mass screening method and counseling for the 1555A→G mitochondrial mutation", J Hum Genet, 44, pp.304~307 (1999)
- 정유승, "갑상선 세침흡인 검체에서 Colorimetric Mutation Detection Method를 이용한 BRAF Mutation검출", 대한외과학회지, 74(1), pp.25~33 (2008), 대한외과학회
- Sommer SS, "A novel method for detecting point mutations or polymorphisms and its application to population screening for carriers of phenylketonuria", Mayo Clin Proc, 64, pp.1361~1372 (1989)
- Hayashi N, "Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method", Cancer Res, 54, pp.3853~3856 (1994)
- Sapio MR, "Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA)", Eur J Endocrinol, 154, pp.341~348 (2006)
- Kumagai A, "Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer", Endocr J, 54, pp.399~405 (2007)
- Chung KW, "Detection of BRAFV600E mutation on fine needle aspiration specimens", Clin Endocrinol (Oxf), 65, pp.660~666 (2006)
- Hegedus L, "The thyroid nodule", N Engl J Med, 351, pp.1764~1771 (2004)
- Oertel YC, "Integrating fine-needle aspiration into a daily practice involving thyroid disorders: the Washington Hospital Center approach", Diagn Cytopathol, 27, pp.120~122 (2002)
- Lee JH, "Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis", Cancer, 110, pp.38~46 (2007)
- Lupi C, "Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma", J Clin Endocrinol Metab, 92, pp.4085~4090 (2007)
- Xing M, "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", J Clin Endocrinol Metab, 90, pp.6373~6379 (2005)
- Kim TY, "The BRAF mutation is useful for prediction of clinical recurrence in low", Clin Endocrinol (Oxf), 65, pp.364~368 (2006)
- Kebebew E, "The prevalence and prognostic value of BRAF mutation in thyroid cancer", Ann Surg, 246, pp.466~471 (2007)
- Park SY, "Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci", Cancer, 107, pp.1831~1838 (2006)